Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MKNK1 Antibodies:
anti-Mouse (Murine) MKNK1 Antibodies:
anti-Rat (Rattus) MKNK1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal MKNK1 Primary Antibody for WB - ABIN2801944
Fukunaga, Hunter: MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. in The EMBO journal 1997
Show all 4 Pubmed References
MNK1 encodes a Ser/Thr protein kinase that interacts with extracellular signal-regulated kinase 1 (show MAPK3 Antibodies) and p38 mitogen-activated protein kinase (show MAPK14 Antibodies), a pathway that is involved in Blood Pressure regulation through norepinephrine and angiotensin II.
Data show that galeterone (gal (show GAL Antibodies)) and VNPT55 inhibit migration and invasion of prostate cancer cells, possibly by down-regulating protein expression via antagonizing the Mnk1/2-eIF4E (show EIF4E Antibodies) axis.
data suggest a physiological role for MNK1a-Ser (show SIGLEC1 Antibodies)(353) phosphorylation in regulation of the MNK1a kinase, which correlates with increased eIF4E (show EIF4E Antibodies) phosphorylation in vitro and in vivo.
Data suggest MNK1/MNK2 (show MKNK2 Antibodies) stimulate mRNA translation but only of mRNA containing both 5-prime-terminal cap and hairpin duplex; this stimulation involves up-regulation of phosphorylation/mRNA un-winding activity of eIF4E (show EIF4E Antibodies) (via decreased binding to eIF4G (show EIF4G1 Antibodies)).
Simultaneous targeting of androgen receptor (show AR Antibodies) and MNK1 by novel retinamides inhibits growth of human prostate cancer cell lines.
MNK1 and MNK2 (show MKNK2 Antibodies) inhibition ablates eIF4E1 (show EIF4E Antibodies) phosphorylation and concurrently enhances eIF4E3 (show EIF4E3 Antibodies) expression in diffuse large B-cell lymphoma.
Data show that interferon-gamma (show IFNG Antibodies) regulated the metabolism and mRNA translation of macrophages by targeting the kinases mTORC1 and MNK1/2, both of which converge on the selective regulator of translation initiation eukaryotic initiation factor-4E (eIF4E (show EIF4E Antibodies)).
Data suggest that a combined pharmacologic inhibition of mTORC1 and Mnk1/2 kinases offers a therapeutic opportunity in blast crisis-chronic myeloid leukemia (BC-CML).
Authors show that MNK (show ATP7A Antibodies) regulates SRPK (show SRPK1 Antibodies) via mTOR (show FRAP1 Antibodies) and AKT (show AKT1 Antibodies).
ERK1/2 (show MAPK1/3 Antibodies) signal induced MNK (show ATP7A Antibodies) catalytic activity enabled enterovirus type 1 internal ribosomal entry site-mediated translation/host cell cytotoxicity through negative regulation of the Ser (show SIGLEC1 Antibodies)/Arg (SR)-rich protein kinase (show CDK7 Antibodies) (SRPK (show SRPK1 Antibodies)).
Cortical neuron-specific deletion of extracellular signal-regulated kinases Erk1 (show MAPK3 Antibodies) or Erk2 (show MAPK1 Antibodies) significantly increased the duration of wakefulness.
pERK1/2 is a regulator of CD44 (show CD44 Antibodies) expression, and increased CD44 (show CD44 Antibodies) expression leads to a pro-sclerotic and migratory parietal epithelial cell phenotype in focal segmental glomerulosclerosis.
mmLDL increased the serum concentrations and expression of ICAM-1 (show ICAM1 Antibodies) and VCAM-1 (show VCAM1 Antibodies) by activating the ERK1/2 (show MAPK1/3 Antibodies) pathway, resulting in the expression of ETB (show EDNRB Antibodies) receptors and the enhancement of contractile function in vascular smooth muscle.
Angiotensin II regulates dendritic cells through activation of p65 NF-kappaB (show NFkBP65 Antibodies), ERK1 (show MAPK3 Antibodies), ERK2 (show MAPK1 Antibodies) and STAT1 (show STAT1 Antibodies) pathways.
MAPK3 (show MAPK3 Antibodies)/1 participates in primordial follicle activation through mTORC1-KITL (show KITLG Antibodies) signaling.
At low oxLDL levels LOX-1 (show OLR1 Antibodies) activates the protective Oct-1 (show POU2F1 Antibodies)/SIRT1 (show SIRT1 Antibodies) pathway, while at higher levels of the lipoprotein switches to the thrombogenic ERK1/2 (show MAPK1/3 Antibodies) pathway.
Studies indicate that progesterone receptor (show PGR Antibodies) transgenic (Pgrcre/+) mitogen inducible gene 6 (Mig (show CXCL9 Antibodies)-6over) phosphatase and tensin homolog (show PTEN Antibodies) protein (Ptenf/f) knockout mice exhibited an increase of phospho-ERK1/2 (show MAPK1/3 Antibodies) and its target genes.
Gpr182 reduction led to increased activation of ERK1/2 in basal and challenge models, demonstrating a potential role for this orphan GPCR in regulating the proliferative capacity of the intestine.
ERK1 (show MAPK3 Antibodies) underexpression is associated with obesity.
retinoschisin (show RS1 Antibodies) is a novel regulator of MAP kinase (show MAPK1 Antibodies) signalling and exerts an anti-apoptotic effect on retinal cells.
This gene encodes a Ser/Thr protein kinase that interacts with, and is activated by ERK1 and p38 mitogen-activated protein kinases, and thus may play a role in the response to environmental stress and cytokines. This kinase may also regulate transcription by phosphorylating eIF4E via interaction with the C-terminal region of eIF4G. Alternatively spliced transcript variants have been noted for this gene.
MAP kinase interacting serine/threonine kinase 1
, MAP kinase-interacting serine/threonine-protein kinase 1
, MAP kinase signal-integrating kinase 1
, MAPK signal-integrating kinase 1
, MAP kinase 1
, MAP kinase 3
, MAP kinase isoform p44
, MAPK 1
, MAPK 3
, extracellular signal-regulated kinase 1
, insulin-stimulated MAP2 kinase
, microtubule-associated protein 2 kinase
, mitogen-activated 3
, mitogen-activated protein kinase 1
, mitogen-activated protein kinase 3
, p44 MAP kinase
, pp42/MAP kinase